US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

 
• By Cathy Kelly
  
Lilly is Seeking Biologics Status for its investigational obesity agent. • Source: Shutterstock
Pink Sheet Podcast

Have you checked out Pink Sheet podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access